Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation

References

• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lip GY. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. Prog Cardiovasc Dis 2015;58:177-94
   PubMed Web of Science ®Google Scholar
• Hsu JC, Akao M, Abe M, et al. International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): rationale, design, and initial descriptives. J Am Heart Assoc 2016;5
   Web of Science ®Google Scholar
• Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017;356:j510. doi: 10.1136/bmj.j510
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lip GY. Postapproval observational studies of non-vitamin K antagonist oral anticoagulants in atrial fibrillation. JAMA 2017;317:1115-1116
   PubMed Web of Science ®Google Scholar
• Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 2016;116:975-986
   PubMed Web of Science ®Google Scholar
• Potpara TS. Dabigatran in “real-world” clinical practice for stroke prevention in patients with non-valvular atrial fibrillation. Thromb Haemost 2015;114:1093-8
   PubMed Web of Science ®Google Scholar
• Staerk L, Fosbol EL, Lip GY, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 2016Oct 14. pii:ehw496. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Camm AJ, Coleman CI, Tamayo S. Rivaroxaban real-world evidence: validating safety and effectiveness in clinical practice. Thromb Haemost 2016;116:S13-23
   PubMed Web of Science ®Google Scholar
• Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke 2017;48:970-976
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-507
   PubMed Web of Science ®Google Scholar
• Schulman S. New oral anticoagulant agents – general features and outcomes in subsets of patients. Thromb Haemost 2014;111:575-82
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Eikelboom JW. The hazards of interrupting anticoagulation therapy in atrial fibrillation. Eur Heart J 2012;33:1864-6
   PubMed Web of Science ®Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2017;117:209-218
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016;5:pii: e003074
   Web of Science ®Google Scholar
• Wang Y, Kong MC, Ko Y. Comparison of three medication adherence measures in patients taking warfarin. J Thromb Thrombolysis 2013;36:416-21
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Sardar P, Giri JS, et al. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 2014;89:896-907
   PubMed Web of Science ®Google Scholar
• Coleman CI, Tangirala M, Evers T. Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. Int J Cardiol 2016;212:171-3
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9
   PubMed Web of Science ®Google Scholar
• Coleman C, Yuan Z, Schein J, et al. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. Curr Med Res Opin 2017; DOI: 10.1080/03007995.2017.1297932
   Google Scholar
• Potpara TS, Pison L, Larsen TB, et al. How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. Europace 2015;17:468-72
   PubMed Web of Science ®Google Scholar